NZ732377B2 - Aminoacid-based composition for fibroelastin recovery in dermal connective tissues - Google Patents
Aminoacid-based composition for fibroelastin recovery in dermal connective tissuesInfo
- Publication number
- NZ732377B2 NZ732377B2 NZ732377A NZ73237715A NZ732377B2 NZ 732377 B2 NZ732377 B2 NZ 732377B2 NZ 732377 A NZ732377 A NZ 732377A NZ 73237715 A NZ73237715 A NZ 73237715A NZ 732377 B2 NZ732377 B2 NZ 732377B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compositions
- valine
- proline
- leucine
- alanine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 18
- 235000001014 amino acid Nutrition 0.000 title claims abstract 8
- 150000001413 amino acids Chemical class 0.000 title claims abstract 8
- 230000002500 effect on skin Effects 0.000 title claims 2
- 210000002808 connective tissue Anatomy 0.000 title 1
- 238000011084 recovery Methods 0.000 title 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract 8
- 229940024606 amino acid Drugs 0.000 claims abstract 7
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000004471 Glycine Substances 0.000 claims abstract 6
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims abstract 6
- 235000019454 L-leucine Nutrition 0.000 claims abstract 6
- 239000004395 L-leucine Substances 0.000 claims abstract 6
- 229930182821 L-proline Natural products 0.000 claims abstract 6
- 229960003767 alanine Drugs 0.000 claims abstract 6
- 229960003136 leucine Drugs 0.000 claims abstract 6
- 229960002429 proline Drugs 0.000 claims abstract 6
- 229960004295 valine Drugs 0.000 claims abstract 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 229960002449 glycine Drugs 0.000 claims abstract 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 206010002961 Aplasia Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 235000019766 L-Lysine Nutrition 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 235000013878 L-cysteine Nutrition 0.000 claims 1
- 239000004201 L-cysteine Substances 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010051246 Photodermatosis Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 206010063562 Radiation skin injury Diseases 0.000 claims 1
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000008845 photoaging Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 229940010747 sodium hyaluronate Drugs 0.000 claims 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000008174 sterile solution Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- -1 transdermal patches Substances 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 102000016942 Elastin Human genes 0.000 abstract 1
- 108010014258 Elastin Proteins 0.000 abstract 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 229920002549 elastin Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Abstract
The present invention relates to compositions containing, as active ingredient, a mixture of amino acids consisting of glycine, L-proline, L-alanine, L-valine, L-leucine and L-lysine hydrochloride, which able to stimulate the biosynthesis of elastin and collagen.
Claims (12)
1. Compositions containing, as active ingredient, a mixture of amino acids consisting of glycine, L-proline, L-alanine, L-valine, L-leucine and L-lysine 5 hydrochloride in the following weight ratios: - Glycine 1; - L-proline: 0.7-0.8; - L-alanine: 0.47-0.76; - L-valine: 0.35-0.56; 10 - L-leucine: 0.13-0.27; - L-lysine hydrochloride: 0.10-0.12.
2. Compositions as claimed in claim 1, also containing L-cysteine or N-acetyl- L-cysteine in percentages by weight ranging between 1 and 20% of the total amino-acid mixture. 15
3. Compositions as claimed in claim 1 or 2 wherein the weight ratios of the amino acids are: - Glycine 1; - L-proline: 0.75; - L-alanine: 0.48-0.51; 20 - L-valine: 0.35-0.37; - L-leucine: 0.13-0.15; - L-lysine hydrochloride: 0.10-0.11.
4. Compositions as claimed in claim 1 or 2 wherein the weight ratios of the amino acids are: 25 - Glycine 1; - L-proline: 0.75; - L-alanine: 0.75-0.76; - L-valine: 0.54-0.56; - L-leucine: 0.13-0.14; - L-lysine hydrochloride: 0.10-0.11.
5. Compositions as claimed in claim 1 or 2 wherein the weight ratios of the amino acids are: 5 - Glycine 1; - L-proline: 0.75; - L-alanine: 0.49-0.51; - L-valine: 0.35-0.36; - L-leucine: 0.26-0.27; 10 - L-lysine hydrochloride: 0.10-0.11.
6. Compositions as claimed in any one of the preceding claims for oral use.
7. Compositions as claimed in claim 6 in the form of solutions, granules, dispersible powder, tablets or capsules.
8. Compositions as claimed in any one of claims 1 to 5, also containing 15 hyaluronic acid or salts thereof, in particular sodium hyaluronate, with an average molecular weight ranging between 500,000 and 3,000,000 Da, in percentages ranging between 0.01 and 3% by weight of the total composition.
9. Compositions as claimed in claim 8 for topical or injective use.
10. Compositions as claimed in claim 9 in the form of gels, ointments, 20 emulsions, transdermal patches, sterile solutions or sterile amino-acid powders designed to be reconstituted with sterile aqueous solutions of hyaluronates.
11. Compositions as claimed in any one of claims 1-10, for use in the treatment of elastosis and dermoepidermal atrophy resulting from photoaging, skin disorders with a dermoatrophic and iatrogenic cause, burns, radiation burns, skin lesions, 25 bedsores, dermal aplasia caused by drug administration, tendon and joint lesions.
12. Compositions as claimed in any one of claims 1-11 substantially as herein described and with reference to any example thereof and with or without reference to the figures. Sheet
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20142084 | 2014-12-04 | ||
PCT/IB2015/059330 WO2016088078A1 (en) | 2014-12-04 | 2015-12-03 | Aminoacid-based composition for fibroelastin recovery in dermal connective tissues |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ732377A NZ732377A (en) | 2023-12-22 |
NZ732377B2 true NZ732377B2 (en) | 2024-03-26 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017118971A (en) | Amino Acid Composition for Restoring Fibroelastin in Dermal Connective Tissues | |
WO2009011544A3 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
WO2010135736A3 (en) | Application and uses of prg4 and therapeutic modulation thereof | |
WO2009106963A3 (en) | Dental composition for preventing and treating stomatitis and mouth ulcers | |
WO2010065709A3 (en) | Hydroxamic acid derivatives, preparation and therapeutic uses thereof | |
NZ601829A (en) | Agent for preventing muscular atrophy | |
EP3501532A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
WO2009022338A3 (en) | Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications | |
WO2012022478A3 (en) | Filler composition comprising beta-glucans | |
PT2459153E (en) | Pharmaceutical or cosmetic or dietetic composition for promoting a hair pigmentation effect | |
WO2009109654A8 (en) | 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1 | |
WO2012161497A3 (en) | Peptide derivatives having a superior moisturizing effect and uses thereof | |
WO2010041832A3 (en) | Antioxidant active composition containing an ishige okamurae-derived compound | |
BR112014027676A2 (en) | [(1s) -1 - {[(2s, 4r) -4- (7-chloro-4-methoxy-isoquinolin-1-yloxy) -2 - ({(1r, 2s) -1 - [(soluble capsule formulation 1,1-dimethylethyl cyclopropylsulfonyl) carbamoyl] -2-ethenylcyclopropyl} carbamoyl) pyrrolidin-1-yl] carbonyl} -2,2-dimethylpropyl] carbamate | |
EA201070315A1 (en) | LIQUID MEDICAL FORM OF CONJUGATE | |
WO2008114376A1 (en) | Melanogenesis inhibitory composition | |
WO2012085249A3 (en) | Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid | |
WO2009106715A3 (en) | Peptide derived from a protein of the aquaporin family | |
WO2010081800A3 (en) | Hylauronic acid containing compositions for treatment of wounds, scars, post-surgical adhesion formation | |
AU2012382949A8 (en) | Compositions and methods for treatment of neuropsychological deficits | |
NZ732377B2 (en) | Aminoacid-based composition for fibroelastin recovery in dermal connective tissues | |
WO2012041261A3 (en) | Peptides from the venom of the rhopalurus junceus scorpion and pharmaceutical composition | |
WO2009070564A3 (en) | Compositions and methods for prevention of infection in transcutaneous osseointegrated implants | |
TN2010000215A1 (en) | Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof | |
WO2010142400A3 (en) | Chitosan oligosaccharide-based compositions |